Disease on EC 1.6.2.4 - NADPH-hemoprotein reductase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Estimation of reference curves for the urinary steroid metabolome in the first year of life in healthy children: Tracing the complexity of human postnatal steroidogenesis.
Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS).
Novel insight into etiology, diagnosis and management of primary adrenal insufficiency.
Role of a Disordered Steroid Metabolome in the Elucidation of Sterol and Steroid Biosynthesis.
Aberrant Crypt Foci
Role of Hepatic and Intestinal P450 Enzymes in the Metabolic Activation of the Colon Carcinogen Azoxymethane in Mice.
Adenocarcinoma
DNA damage induced by NADPH cytochrome P450 reductase-activated idarubicin in sensitive and multidrug resistant MCF7 breast cancer cells.
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: Possible mechanisms involved.
Adrenal Hyperplasia, Congenital
46,XX DSD and Antley-Bixler syndrome due to novel mutations in the cytochrome P450 oxidoreductase gene.
A male twin infant with skull deformity and elevated neonatal 17-hydroxyprogesterone: a prismatic case of P450 oxidoreductase deficiency.
A rare cause of congenital adrenal hyperplasia: Antley-Bixler syndrome due to POR deficiency.
Alternative pathway androgen biosynthesis and human fetal female virilization.
Assisted Reproduction in Congenital Adrenal Hyperplasia.
Clinical implications of androgen synthesis via 5alpha-reduced precursors.
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency.
Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.
Congenital adrenal hyperplasia owing to 17?-hydroxylase/17,20 lyase and p450 oxidoreductase deficiencies.
Disorders of sexual development in a cultural context.
Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Impact of molecular genetics on congenital adrenal hyperplasia management.
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Linking Antley-Bixler syndrome and congenital adrenal hyperplasia: a novel case of P450 oxidoreductase deficiency.
Long-term follow-up of a female with congenital adrenal hyperplasia due to P450-oxidoreductase deficiency.
MECHANISMS IN ENDOCRINOLOGY: Update on pathogenesis of primary adrenal insufficiency: beyond steroid enzyme deficiency and autoimmune adrenal destruction.
Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.
Novel phenotypes and genotypes in Antley-Bixler syndrome caused by cytochrome P450 oxidoreductase deficiency: based on the first cohort of Chinese children.
P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia.
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia.
P450 Oxidoreductase Deficiency: loss of activity caused by protein instability from a novel L374H mutation.
Prenatal diagnosis of congenital adrenal hyperplasia caused by p450 oxidoreductase deficiency.
Pubertal Presentation in Seven Patients with Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency.
Adrenal Insufficiency
Clinical and biochemical consequences of p450 oxidoreductase deficiency.
P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia.
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia.
Androgen-Insensitivity Syndrome
Disorders of sexual development in a cultural context.
Antley-Bixler Syndrome Phenotype
46,XX DSD and Antley-Bixler syndrome due to novel mutations in the cytochrome P450 oxidoreductase gene.
A case of Antley-Bixler syndrome caused by compound heterozygous mutations of the cytochrome P450 oxidoreductase gene.
Altered Human CYP3A4 Activity Caused by Antley-Bixler Syndrome-Related Variants of NADPH-Cytochrome P450 Oxidoreductase Measured in a Robust In Vitro System.
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
Anorectal and urinary anomalies and aberrant retinoic acid metabolism in cytochrome P450 oxidoreductase deficiency.
Backdoor pathway for dihydrotestosterone biosynthesis: Implications for normal and abnormal human sex development.
Basic concepts and recent developments in human steroid hormone biosynthesis.
Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome.
Conditional Deletion of Cytochrome P450 Reductase in Osteoprogenitor Cells Affects Long Bone and Skull Development in Mice Recapitulating Antley-Bixler Syndrome: Role of a Redox Enzyme in Development.
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Cytochrome P450 oxidoreductase deficiency with Antley-Bixler syndrome: steroidogenic capacities.
Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients.
Cytochrome P450 Oxidoreductase Deficiency: Novel Cause of Ambiguity with Primary Amenorrhea.
Cytochrome P450 oxidoreductase deficiency: rare congenital disorder leading to skeletal malformations and steroidogenic defects.
Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.
Cytochromes P450--a family of proteins and scientists-understanding their relationships.
Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase.
Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.
Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase.
In vitro fertilization-frozen embryo transfer in a patient with cytochrome P450 oxidoreductase deficiency: a case report.
Linking Antley-Bixler syndrome and congenital adrenal hyperplasia: a novel case of P450 oxidoreductase deficiency.
Mouse Knockout of the Cholesterogenic Cytochrome P450 Lanosterol 14{alpha}-Demethylase (Cyp51) Resembles Antley-Bixler Syndrome.
Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.
Novel phenotypes and genotypes in Antley-Bixler syndrome caused by cytochrome P450 oxidoreductase deficiency: based on the first cohort of Chinese children.
P450 oxidoreductase deficiency and Antley-Bixler syndrome.
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia.
P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Pharmacogenomics of human P450 oxidoreductase.
Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype.
The mechanism of Psoralen and Isopsoralen hepatotoxicity as revealed by hepatic gene expression profiling in SD rats.
Two-Step Biochemical Differential Diagnosis of Classic 21-Hydroxylase Deficiency and Cytochrome P450 Oxidoreductase Deficiency in Japanese Infants by GC-MS Measurement of Urinary Pregnanetriolone/ Tetrahydroxycortisone Ratio and 11?-Hydroxyandrosterone.
Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone.
[Antley-Bixler syndrome or POR deficiency?]
aromatase deficiency
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Ascorbic Acid Deficiency
The effect of certain vitamin deficiencies on hepatic drug metabolism.
Breast Neoplasms
A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans.
Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues.
CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors.
Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: Possible mechanisms involved.
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Role of NADPH cytochrome P450 reductase in activation of RH1.
Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.
Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
Carcinogenesis
Characterization of an acute molecular marker of nongenotoxic rodent hepatocarcinogenesis by gene expression profiling in a long term clofibric acid study.
Superoxide radical generation from heterocyclic amines.
Carcinoma
Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer.
Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors.
DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
[DT-diaphorase]
Carcinoma, Hepatocellular
Characterization of NADPH-cytochrome P-450 reductase in a mouse hepatoma cell line.
Drug metabolism in the Novikoff hepatoma: evidence for a mixed function oxidase system and partial purification of cytochrome P-450 reductase.
Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
Mechanisms of NADPH-cytochrome P450 oxidoreductase induction by dexamethasone in the H4IIE rat hepatoma cell line.
NADPH-cytochrome P-450 reductase is involved in flunitrazepam reductive metabolism in Hep G2 and Hep 3B cells.
Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
Preparation of homogeneous NADPH-cytochrome P-450 reductase from rat hepatoma.
Suppression of cytochrome P450 reductase expression in hepatoma cells replicates the hepatic lipidosis observed in hepatic POR-null mice.
The drug metabolism systems of liver and liver tumors: a comparison of activities and characteristics.
Thyroid regulation of NADPH:cytochrome P450 oxidoreductase: identification of a thyroid-responsive element in the 5'-flank of the oxidoreductase gene.
Carcinoma, Non-Small-Cell Lung
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Carcinoma, Ovarian Epithelial
Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
Cardiotoxicity
A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.
Chagas Disease
cDNA Isolation and Expression of Nicotinamide Adenine Dinucleotide Phosphate-Dependent Cytochrome P450 Reductase Gene in the Chagas Disease Vector
Cholestasis
Microsomal function in biliary obstructed rats: effects of S-adenosylmethionine.
Cholestasis, Intrahepatic
Selective reduction of hepatic cytochrome P450 content in patients with intrahepatic cholestasis. A mechanism for impairment of microsomal drug oxidation.
Coinfection
Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell system.
Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants.
Expression and coupling of human cytochrome P450 2E1 and NADPH-cytochrome P450 oxidoreductase in dual expression and co-infection systems with baculovirus in insect cells.
Colitis
Intestinal epithelium-specific knockout of the cytochrome P450 reductase gene exacerbates dextran sulfate sodium-induced colitis.
Colonic Neoplasms
Regulatory network of mitomycin C action in human colon cancer cells.
The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Congenital Abnormalities
A male twin infant with skull deformity and elevated neonatal 17-hydroxyprogesterone: a prismatic case of P450 oxidoreductase deficiency.
Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to its Antley-Bixler Syndrome-Like Phenotype.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Cytochrome P450 oxidoreductase deficiency: rare congenital disorder leading to skeletal malformations and steroidogenic defects.
Craniosynostoses
Clinical and biochemical consequences of p450 oxidoreductase deficiency.
P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia.
Disorders of Sex Development
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
Clinical, Genetic, and Enzymatic Characterization of P450 Oxidoreductase Deficiency in Four Patients.
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency.
Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients.
Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase.
Disorder of sex development as a diagnostic clue in the first Spanish known newborn with P450 oxidoreductase deficiency.
Genetics of congenital adrenal hyperplasia.
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia.
P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
[Rare forms of female pseudohermaphroditism: when to investigate?]
Encephalitis
Distribution of hammerhead and hammerhead-like RNA motifs through the GenBank.
Encephalomyelitis
Quantifying immunohistochemical staining of phospho-eIF2alpha, heme oxygenase-2 and NADPH cytochrome P450 reductase in oligodendrocytes during experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Heme oxygenase-1 and NADPH cytochrome P450 reductase expression in experimental allergic encephalomyelitis: an expanded view of the stress response.
Quantifying immunohistochemical staining of phospho-eIF2alpha, heme oxygenase-2 and NADPH cytochrome P450 reductase in oligodendrocytes during experimental autoimmune encephalomyelitis.
Epilepsy
Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy.
Fanconi Anemia
Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase.
Do Fanconi anemia genes control cell response to cross-linking agents by modulating cytochrome P-450 reductase activity?
Fatty Liver
Defining a relationship between dietary fatty acids and the cytochrome P450 system in a mouse model of fatty liver disease.
Fibrosarcoma
Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.
Genetic Diseases, Inborn
P450 Oxidoreductase Deficiency: A Systematic Review and Meta-analysis of Genotypes, Phenotypes, and Their Relationships.
Glioma
Expression, induction and regulation of the cytochrome P450 monooxygenase system in the rat glioma C6 cell line.
Glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma.
Identification of inducible mixed function oxidase system in rat glioma C6 cell line.
Gliosarcoma
Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Gonadal Dysgenesis
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Granulomatous Disease, Chronic
Subcellular localization of the human neutrophil NADPH oxidase. b-Cytochrome and associated flavoprotein.
Hepatitis B
Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
Hepatitis C
Engineered retargeting of viral RNA replication complexes to an alternative intracellular membrane.
Hepatitis E
Distribution of hammerhead and hammerhead-like RNA motifs through the GenBank.
Herpes Zoster
Androgen synthesis in adrenarche.
Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies.
Levels of adrenodoxin, NADPH-cytochrome P-450 reductase and cytochromes P-45011 beta, P-45021, P-450scc, in adrenal zona fasciculata-reticularis tissue from androgen-treated rats.
Relationships between NADPH diaphorase staining and neuronal, endothelial, and inducible nitric oxide synthase and cytochrome P450 reductase immunoreactivities in guinea-pig tissues.
Zonal distribution of cytochromes P-450 and related enzymes of bovine adrenal cortex--quantitative assay of concentrations and total contents.
Huntington Disease
Preimplantation genetic diagnosis of P450 oxidoreductase deficiency and Huntington Disease using three different molecular approaches simultaneously.
Hyperthyroidism
Evaluation of thyroid hormone effects on liver P450 reductase translation.
Lipid peroxidation in rat liver microsomes. I. Stimulation of the NADPH-cytochrome P-450 reductase-dependent process in hyperthyroid state.
Infections
An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux.
Effects of Plasmodium berghei infection on cytochromes P-450 2E1 and 3A2.
[CYP2D6*1, CYP2D6*10 co-expressed with CYPOR in Bac-to-Bac expression system and activity determination].
Infertility
Clinical, Genetic, and Enzymatic Characterization of P450 Oxidoreductase Deficiency in Four Patients.
Iron Overload
Enhancement by iron of hepatic neoplasia in rats caused by hexachlorobenzene.
Leukemia, Myeloid, Acute
A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.
Lipidoses
Suppression of cytochrome P450 reductase expression in hepatoma cells replicates the hepatic lipidosis observed in hepatic POR-null mice.
Liver Neoplasms, Experimental
Drug metabolism in the Novikoff hepatoma: evidence for a mixed function oxidase system and partial purification of cytochrome P-450 reductase.
The drug metabolism systems of liver and liver tumors: a comparison of activities and characteristics.
Lung Injury
Inhibition of NADPH cytochrome P450 reductase by the model sulfur mustard vesicant 2-chloroethyl ethyl sulfide is associated with increased production of reactive oxygen species.
Lung Neoplasms
A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors.
Malaria
Biochemical comparison of Anopheles gambiae and human NADPH P450 reductases reveals different 2'-5'-ADP and FMN binding traits.
Effects of Plasmodium berghei infection on cytochromes P-450 2E1 and 3A2.
Melanoma
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.
The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
nadph-hemoprotein reductase deficiency
A male twin infant with skull deformity and elevated neonatal 17-hydroxyprogesterone: a prismatic case of P450 oxidoreductase deficiency.
Age-specific changes in sex steroid biosynthesis and sex development.
Alternative pathway androgen biosynthesis and human fetal female virilization.
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
Anorectal and urinary anomalies and aberrant retinoic acid metabolism in cytochrome P450 oxidoreductase deficiency.
Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency.
Backdoor pathway for dihydrotestosterone biosynthesis: Implications for normal and abnormal human sex development.
Basic concepts and recent developments in human steroid hormone biosynthesis.
Classic and non-classic 21-hydroxylase deficiency can be discriminated from P450 oxidoreductase deficiency in Japanese infants by urinary steroid metabolites.
Clinical and biochemical consequences of p450 oxidoreductase deficiency.
Clinical implications of androgen synthesis via 5alpha-reduced precursors.
Clinical, Genetic, and Enzymatic Characterization of P450 Oxidoreductase Deficiency in Four Patients.
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency.
Congenital adrenal hyperplasia owing to 17?-hydroxylase/17,20 lyase and p450 oxidoreductase deficiencies.
Congenital adrenal hyperplasia: clinical symptoms and diagnostic methods.
Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Cytochrome P450 oxidoreductase deficiency with Antley-Bixler syndrome: steroidogenic capacities.
Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients.
Cytochrome P450 Oxidoreductase Deficiency: Novel Cause of Ambiguity with Primary Amenorrhea.
Cytochrome P450 oxidoreductase deficiency: rare congenital disorder leading to skeletal malformations and steroidogenic defects.
Delayed diagnosis of disorder of sex development (DSD) due to P450 oxidoreductase (POR) deficiency.
Disorder of sex development as a diagnostic clue in the first Spanish known newborn with P450 oxidoreductase deficiency.
Disorders of sexual development in a cultural context.
Effect of Cytochrome P450 Reductase Deficiency on 2-Amino-9H-pyrido[2,3-b]indole Metabolism and DNA Adduct Formation in Liver and Extrahepatic Tissues of Mice.
Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: Functional Basis of P450 Oxidoreductase Deficiency.
Estimation of reference curves for the urinary steroid metabolome in the first year of life in healthy children: Tracing the complexity of human postnatal steroidogenesis.
Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS).
Genetic and Clinical Features of P450 Oxidoreductase Deficiency.
Genetics of congenital adrenal hyperplasia.
Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
In vitro fertilization-frozen embryo transfer in a patient with cytochrome P450 oxidoreductase deficiency: a case report.
Linking Antley-Bixler syndrome and congenital adrenal hyperplasia: a novel case of P450 oxidoreductase deficiency.
Long-term follow-up of a female with congenital adrenal hyperplasia due to P450-oxidoreductase deficiency.
Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization.
Novel insight into etiology, diagnosis and management of primary adrenal insufficiency.
Novel phenotypes and genotypes in Antley-Bixler syndrome caused by cytochrome P450 oxidoreductase deficiency: based on the first cohort of Chinese children.
P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia.
P450 oxidoreductase deficiency and Antley-Bixler syndrome.
P450 oxidoreductase deficiency with maternal virilization during pregnancy.
P450 oxidoreductase deficiency.
P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes.
P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations.
P450 oxidoreductase deficiency: a new disorder of steroidogenesis.
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia.
P450 Oxidoreductase Deficiency: A Systematic Review and Meta-analysis of Genotypes, Phenotypes, and Their Relationships.
P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
P450 Oxidoreductase Deficiency: loss of activity caused by protein instability from a novel L374H mutation.
Pharmacogenomics of human P450 oxidoreductase.
Preimplantation genetic diagnosis of P450 oxidoreductase deficiency and Huntington Disease using three different molecular approaches simultaneously.
Prenatal diagnosis of congenital adrenal hyperplasia caused by p450 oxidoreductase deficiency.
Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype.
Pubertal Presentation in Seven Patients with Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency.
Role of a Disordered Steroid Metabolome in the Elucidation of Sterol and Steroid Biosynthesis.
Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency.
The mechanism of Psoralen and Isopsoralen hepatotoxicity as revealed by hepatic gene expression profiling in SD rats.
Two-Step Biochemical Differential Diagnosis of Classic 21-Hydroxylase Deficiency and Cytochrome P450 Oxidoreductase Deficiency in Japanese Infants by GC-MS Measurement of Urinary Pregnanetriolone/ Tetrahydroxycortisone Ratio and 11?-Hydroxyandrosterone.
Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone.
Neoplasm Metastasis
CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
The ancient cell death suppressor BAX inhibitor-1.
Neoplasms
Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer.
Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554).
Capsaicin alleviates the imbalance in xenobiotic metabolizing enzymes and tumor markers during experimental lung tumorigenesis.
Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues.
Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer.
Chemopreventive effect of Ginkgo biloba extract against benzo(a)pyrene-induced forestomach carcinogenesis in mice: amelioration of doxorubicin cardiotoxicity.
Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Cytochrome P450 CYP1B1 activity in renal cell carcinoma.
Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis.
Cytochrome P450-based cancer gene therapy: recent advances and future prospects.
Dietary influences on rat hepatic and intestinal DT-diaphorase activity.
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors.
Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity.
Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors.
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Effects of phenobarbital and 3-methylcolanthrene treatment on microsomes of Morris hepatoma 3924-A, tumour-bearing and normal rat liver.
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase.
Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development.
Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man.
Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.
Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.
Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.
KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation.
Localized aberrant expression of cytochrome P450 aromatase in primary and metastatic malignant tumors of human liver.
Mechanisms of Anthracycline-Enhanced Reactive Oxygen Metabolism in Tumor Cells.
Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects.
Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
P450 enzyme expression patterns in the NCI human tumor cell line panel.
Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.
Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression.
Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors.
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Role of NADPH cytochrome P450 reductase in activation of RH1.
Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia.
Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase. Implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells.
Superoxide radical generation from heterocyclic amines.
The ancient cell death suppressor BAX inhibitor-1.
The drug metabolism systems of liver and liver tumors: a comparison of activities and characteristics.
The enzymology of doxorubicin quinone reduction in tumour tissue.
The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
The mechanism of Psoralen and Isopsoralen hepatotoxicity as revealed by hepatic gene expression profiling in SD rats.
The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748.
The role of bioreductive activation of antitumour anthracycline drugs in cytotoxic activity against sensitive and multidrug resistant leukaemia HL60 cells.
The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.
The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.
Transforming growth factor-beta in in vivo resistance.
Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
Xenobiotic metabolizing enzymes in genetically and chemically initiated mouse liver tumors.
Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
Neurodegenerative Diseases
Localization of NADPH cytochrome P450 oxidoreductase in rat brain by immunohistochemistry and in situ hybridization and a comparison with the distribution of neuronal NADPH-diaphorase staining.
Obesity
Induction of cytochrome P450IIE1 in the obese overfed rat.
Ovarian Diseases
Clinical implications of androgen synthesis via 5alpha-reduced precursors.
Ovarian Neoplasms
Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
Ovotesticular Disorders of Sex Development
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Pancreatic Neoplasms
The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748.
Polycystic Ovary Syndrome
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia.
Retinal Degeneration
[Changes in cytochrome P-450 and NADPH-cytochrome P-450 reductase in hereditary retinal degeneration in rats]
Riboflavin Deficiency
Lipid metabolism in riboflavin-deficient rats. 2. Mitochondrial fatty acid oxidation and the microsomal desaturation pathway.
Sarcoma
Effect of extra-hepatic Walker sarcoma 256 on the synthesis and degradation of liver cytochromes P-450 and b5.
Starvation
Induction and regulation of cytochrome P450 K-5 (lauric acid hydroxylase) in rat renal microsomes by starvation.
steroid 11beta-monooxygenase deficiency
Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.
steroid 17alpha-monooxygenase deficiency
Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency.
steroid 21-monooxygenase deficiency
Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency.
Backdoor pathway for dihydrotestosterone biosynthesis: Implications for normal and abnormal human sex development.
Classic and non-classic 21-hydroxylase deficiency can be discriminated from P450 oxidoreductase deficiency in Japanese infants by urinary steroid metabolites.
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency.
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Prenatal diagnosis of congenital adrenal hyperplasia caused by p450 oxidoreductase deficiency.
The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.
Two-Step Biochemical Differential Diagnosis of Classic 21-Hydroxylase Deficiency and Cytochrome P450 Oxidoreductase Deficiency in Japanese Infants by GC-MS Measurement of Urinary Pregnanetriolone/ Tetrahydroxycortisone Ratio and 11?-Hydroxyandrosterone.
Stroke
Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation.
Synostosis
Regulation of gap junction function and Connexin 43 expression by cytochrome P450 oxidoreductase (CYPOR).
Triple Negative Breast Neoplasms
CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Urinary Bladder Diseases
Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors.
Urinary Bladder Neoplasms
Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolizing activity of "luminal" muscle-invasive bladder cancers.
Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors.
Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.
Urogenital Abnormalities
Mouse Knockout of the Cholesterogenic Cytochrome P450 Lanosterol 14{alpha}-Demethylase (Cyp51) Resembles Antley-Bixler Syndrome.
Vaccinia
Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7.